filmov
tv
Past and Future Therapy for Hepatitis C
Показать описание
Past and Future Therapy for Hepatitis C
Air date: Wednesday, November 12, 2014, 3:00:00 PM
Category: WALS - Wednesday Afternoon Lectures
Runtime: 00:53:03
Description: Wednesday Afternoon Lecture
Annual Astute Clinician Lecture
The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil.
He has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.
Author: Jay H. Hoofnagle, M.D., Director, Liver Disease Research Branch, NIDDK, NIH
Air date: Wednesday, November 12, 2014, 3:00:00 PM
Category: WALS - Wednesday Afternoon Lectures
Runtime: 00:53:03
Description: Wednesday Afternoon Lecture
Annual Astute Clinician Lecture
The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil.
He has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.
Author: Jay H. Hoofnagle, M.D., Director, Liver Disease Research Branch, NIDDK, NIH
0:53:03
0:01:41
0:16:29
0:04:02
0:33:16
0:02:15
0:00:59
0:17:25
0:22:32
0:10:50
0:16:32
0:04:09
0:00:51
1:12:48
0:17:41
0:00:20
0:57:58
0:10:09
0:00:17
0:29:34
0:00:43
0:44:31
0:27:12
0:03:28